Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros ...

The Japanese pharma has been building a presence in oncology over the last few years through products such as its Adcetris (brentuximab vedotin), and its $5.2 billion acquisition of Ariad at the ...

Joan S. Brugge (Ariad Pharmaceuticals Inc., Cambridge, Mass.): "Growth factor activation of receptor protein tyrosine kinases induces tyrosine phosphorylation of MAP kinases (MAPKs). MAPKs have been ...

The Japanese pharma company acquired Ariad a year ago for $5.2bn, and the latest, more modest acquisition, shows that Takeda's chief Christophe Weber sees buy-outs as ongoing route to growth.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...